Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds

被引:66
作者
Munayyer, HK [1 ]
Mann, PA [1 ]
Chau, AS [1 ]
Yarosh-Tomaine, T [1 ]
Greene, JR [1 ]
Hare, RS [1 ]
Heimark, L [1 ]
Palermo, RE [1 ]
Loebenberg, D [1 ]
McNicholas, PM [1 ]
机构
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
关键词
D O I
10.1128/AAC.48.10.3690-3696.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Posaconazole (POS; SCH 56592) is a novel triazole that is active against a wide variety of fungi, including fluconazole-resistant Candida albicans isolates and fungi that are inherently less susceptible to approved azoles, such as Candida glabrata. In this study, we compared the effects of POS, itraconazole (ITZ), fluconazole (FLZ), and voriconazole (VOR) on sterol biosynthesis in strains of C. albicans (both azole-sensitive and azole-resistant strains), C. glabrata, Aspergillus fumigatus, and Aspergillus flavus. Following exposure to azoles, nonsaponifitable sterols were extracted and resolved by liquid chromatography and sterol identity was confirmed by mass spectroscopy. Ergosterol was the major sterol in all but one of the strains; C. glabrata strain C110 synthesized an unusual sterol in place of ergosterol. Exposure to POS led to a decrease in the total sterol content of all the strains tested. The decrease was accompanied by the accumulation of 14alpha-methylated sterols, supporting the contention that POS inhibits the cytochrome P450 14alpha-demethylase enzyme. The degree of sterol inhibition was dependent on both dose and the susceptibility of the strain tested. POS retained activity against C. albicans isolates with mutated forms of the 14alpha-demethylase that rendered these strains resistant to FLZ, ITZ, and VOR. In addition, POS was a more potent inhibitor of sterol synthesis in A. fumigatus and A. flavus than either ITZ or VOR.
引用
收藏
页码:3690 / 3696
页数:7
相关论文
共 21 条
[1]   In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida [J].
Cacciapuoti, A ;
Loebenberg, D ;
Corcoran, E ;
Menzel, F ;
Moss, EL ;
Norris, C ;
Michalski, M ;
Raynor, K ;
Halpern, J ;
Mendrick, C ;
Arnold, B ;
Antonacci, B ;
Parmegiani, R ;
Yarosh-Tomaine, T ;
Miller, GH ;
Hare, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2017-2022
[2]   Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to Azoles [J].
Chau, AS ;
Mendrick, CA ;
Sabatelli, FJ ;
Loebenberg, D ;
McNicholas, PM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2124-2131
[3]   Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance [J].
Ghannoum, MA ;
Rice, LB .
CLINICAL MICROBIOLOGY REVIEWS, 1999, 12 (04) :501-+
[4]   Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis [J].
Heimark, L ;
Shipkova, P ;
Greene, J ;
Munayyer, H ;
Yarosh-Tomaine, T ;
DiDomenico, B ;
Hare, R ;
Pramanik, BN .
JOURNAL OF MASS SPECTROMETRY, 2002, 37 (03) :265-269
[5]  
Hitchcock CA, 1993, CUTANEOUS ANTIFUNGAL, P183
[6]   Effects of voriconazole on Candida glabrata in vitro [J].
Koul, A ;
Vitullo, J ;
Reyes, G ;
Ghannoum, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (01) :109-112
[7]   Aspergillosis case - Fatality rate: Systematic review of the literature [J].
Lin, SJ ;
Schranz, J ;
Teutsch, SM .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :358-366
[8]   A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592) [J].
Manavathu, EK ;
Cutright, JL ;
Loebenberg, D ;
Chandrasekar, PH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (02) :229-234
[9]   Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates [J].
Marichal, P ;
Gorrens, J ;
Laurijssens, L ;
Vermuyten, K ;
Van Hove, C ;
Le Jeune, L ;
Verhasselt, P ;
Sanglard, D ;
Borgers, M ;
Ramaekers, FCS ;
Odds, F ;
Vanden Bossche, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2663-2670
[10]  
MARICHAL P, 1984, J MED VET MYCOLOGY, V22, P13